References of "Cormier, C"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailOverestimation of the 25OHD serum concentration with the automated IDS EIA kit.
Cavalier, Etienne ULg; Huberty, V.; Cormier, C. et al

in Journal of Bone and Mineral Research (2011), 26(2), 434-6

We have recently observed an increasing number of patients presenting very high serum levels of 25-hydroxyvitamin D [25(OH)D] (> 150 ng/mL), which, in all cases, had been measured with the IDS EIA kit ... [more ▼]

We have recently observed an increasing number of patients presenting very high serum levels of 25-hydroxyvitamin D [25(OH)D] (> 150 ng/mL), which, in all cases, had been measured with the IDS EIA kit adapted on different "open" automated platforms. We performed a comparison between the IDS EIA kit adapted on two different "open"automated platforms and the DiaSorin RIA. We found a systematic bias (higher levels with the IDS EIA kit) for concentrations more than 50-60 ng/mL that was less obvious when the IDS EIA was used in its manual procedure. We thus suggest to use the IDS EIA kit in its manual procedure rather than to adapt it on an automated platform, and to interpret cautiously a 25(OH)D greater than 100 ng/mL with this kit. [less ▲]

Detailed reference viewed: 39 (1 ULg)
Full Text
Peer Reviewed
See detailRelationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.
Bruyère, Olivier ULg; Collette, Julien ULg; Rizzoli, R. et al

in Osteoporosis International (2010), 21

From two randomised controlled trials, it is shown that 3-month changes in biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) were ... [more ▼]

From two randomised controlled trials, it is shown that 3-month changes in biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) were associated with 3-year bone mineral density (BMD) changes, but not fracture incidence in patients treated with strontium ranelate. INTRODUCTION: The purpose of this study was to assess if short-term change in biochemical markers of bone remodelling is associated with long-term BMD change and fracture incidence observed during treatment with strontium ranelate. METHODS: From the SOTI and TROPOS trials, bone-specific alkaline phosphatase (BALP), C-terminal propeptide of type I procollagen (PICP), serum C-terminal telopeptides (S-CTX) and urine N-terminal telopeptides of type I collagen (U-NTX) were assessed at baseline and after 3 months. RESULTS: Two thousand three hundred seventy-three women were included in this study. Multiple regression analysis showed that 3-month changes in PICP and BALP but not s-CTX I nor s-NTX I were significantly (p < 0.001) associated with 3-year BMD changes at the lumbar spine and the femoral neck. Changes in s-CTX I, PICP and BALP were significantly associated with change in total proximal femur BMD. Changes in biochemical markers explain less than 8% of the BMD changes. The 3-month changes in BALP, PICP s-CTX I and s-NTX I were not significantly associated with fracture incidence. CONCLUSIONS: Short-term changes in biochemical markers of bone formation are associated with future BMD changes in patients treated with strontium ranelate, suggesting a bone-forming activity of this treatment, but are not appropriate to monitor the efficacy of strontium ranelate at the individual level. [less ▲]

Detailed reference viewed: 42 (19 ULg)
Full Text
Peer Reviewed
See detailEffects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier, Pierre; Roux, C.; Ortolani, S. et al

in Osteoporosis International (2009), 20

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33 ... [more ▼]

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. INTRODUCTION: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. METHODS: A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated. RESULTS: Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction = 0.67, p < 0.001). Among patients with two or more prevalent vertebral fractures, risk reduction was 36% (p < 0.001). QoL, assessed by the QUALIOST(R), was significantly better (p = 0.025), and patients without back pain were greater (p = 0.005) with strontium ranelate than placebo over 4 years. Lumbar BMD increased over 5 years in patients who continued with strontium ranelate, while it decreased in patients who switched to placebo. Emergent adverse events were similar between groups. CONCLUSION: In this 4- and 5-year study, strontium ranelate is an effective and safe treatment for long-term treatment of osteoporosis in postmenopausal women. [less ▲]

Detailed reference viewed: 48 (11 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate decreases the risk of hip fracture over 3 and 5 years in post menopausal women at high risk
Reginster, Jean-Yves ULg; Felsenberg, D.; Boonen, Steven et al

in Annals of the Rheumatic Diseases (2008, June), 67(Suppl.II), 540

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate demonstrates efficacy against hip fracture over 3 and 5 years in postmenopausal women at high risk of hip fracture
Reginster, Jean-Yves ULg; Felsenberg, D.; Boonen, Steven et al

in Osteoporosis International (2008, April), 19(Suppl.1), 26-27

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailLong term efficacy of strontium ranelate in reducing the risk of vertebral and non-vertebral including hip fractures in post menopausal osteoporotic women over 5 years
Reginster, Jean-Yves ULg; Brixen, Kim; Cormier, C. et al

in Annals of the Rheumatic Diseases (2007, June), 66(Suppl.II), 102

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate demonstrates vertebral and non-vertebral antifracture efficacy including hip fractures over 5 years in postmenopausal osteoporotic women
Reginster, Jean-Yves ULg; Brixen, Kim; Cormier, C. et al

in Calcified Tissue International (2007, May), 80(Suppl.1), 47

Detailed reference viewed: 13 (3 ULg)
Full Text
Peer Reviewed
See detailCorrélation entre l'augmentation de la densité minérale osseuse et la réduction du risque fracturaire lors d'un traitement par ranélate de strontium
Bruyère, Olivier ULg; Cormier, C.; Fardellone, Patrice et al

in Revue du Rhumatisme (2006, December), 73

Detailed reference viewed: 7 (4 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate demonstrates vertebral and non-vertebral ANTI fracture efficacy including hip fractures over 5 years in post menopausal osteoporotic women
Reginster, Jean-Yves ULg; Brixen, Kim; Cormier, C. et al

in Osteoporosis International (2006, March), 18(Suppl.1), 21

Detailed reference viewed: 16 (9 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate réduit le risque de fracture vertébrale chez des patientes traitées 3 ans pour ostéoporose postménopausique
Meunier, P. J.; Roux, C.; Fardellone, P. et al

in Revue du Rhumatisme (2002), 69

Detailed reference viewed: 9 (2 ULg)